#China #Shanghai #CARsgen #GPC3 CAR-T #European Patent

CARsgen Therapeutics Patent Protection Update

In a significant development for CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), the company has achieved a substantial victory by securing the validity of its GPC3-targeted CAR-T cell therapy patent at the European Patent Office (EPO). This victory not only reinforces CARsgen's intellectual property standing but also positions it favorably within the competitive landscape of cancer treatment options.

Summary of the Patent Proceedings

On July 3, 2025, the only remaining opponent, a U.S.-based biotechnology firm, decided to withdraw its appeal following the EPO Opposition Division's favorable decision regarding the patent EP3445407. This withdrawal effectively concludes the opposition proceedings and confirms the EPO's ruling that preserves key claims related to the use of CAR-T therapy targeting GPC3, particularly in treating various solid tumors such as liver, lung, ovarian, breast, gastric, and thyroid cancers.

The patent, initially granted in 2022, faced opposition from two parties starting in 2023. After rigorous oral proceedings, the EPO determined that the patent should be maintained but in an amended form, ensuring the continuation of imperative aspects of the therapy’s claims.

Impact on CARsgen’s Operations

The outcome of these proceedings significantly enhances CARsgen's operational footing and capabilities in the CAR-T field. With the EPO decision now final, the competitors or any third parties are precluded from challenging this patent again at the EPO level. Such stability is critical for CARsgen as it continues to innovate and expand its product pipeline.

CARsgen is dedicated to addressing unmet clinical needs with its innovative CAR T-cell therapies, particularly in areas related to hematological malignancies, solid tumors, and autoimmune conditions. This patent victory is a step towards fulfilling its mission of becoming a global leader in biopharmaceuticals.

The Significance of GPC3-targeted CAR-T Therapies

GPC3-targeted CAR-T therapies represent a groundbreaking approach to treating solid tumors, which historically have posed challenges for existing cancer treatments. By targeting GPC3, CARsgen’s therapy aims to enhance the precision and efficacy of treatments for patients facing cancer.

Furthermore, CARsgen is actively working on refining these therapies to improve safety profiles, increase treatment efficacy, and reduce associated costs. This commitment highlights the company’s focus on innovation and quality care delivery for cancer patients globally.

Conclusion

In summary, CARsgen Therapeutics has successfully navigated a complex patent landscape, obtaining a critical victory that secures its proprietary technologies and consent for its CAR-T therapies. As CARsgen moves forward, this legal triumph will likely bolster investor confidence, facilitate further research development efforts, and amplify CARsgen's reputation within the biopharmaceutical sector. The company’s resolve to provide innovative therapies remains steadfast in addressing the pressing challenges of cancer care, ensuring a positive outlook for its future endeavors.

For more information about CARsgen and its initiatives, please visit CARsgen Therapeutics.